Publication Date

Spring 2012

Document Type

Project Summary

Degree Name

Master of Science


Analytical Chemistry

First Advisor

Walter Henne, Jr., Ph.D.

Second Advisor

Patty Fu-Giles, Ph.D.

Third Advisor

Stephen Kent, M.B.A.


The folate receptor is overexpressed on the surface of numerous cancer cell types including those of the breast, lung, kidney, ovary, and brain. Recent interest has exploded in the use of folate to deliver payloads and imaging agents to folate receptor positive cancer cells based on several positive clinical trials including phase III trials of EC-145, which is poised to become the first folate targeted, FDA approved drug. Given the success of EC-145 and numerous other agents in the pharmaceutical pipeline, there remains a great interest in the exploitation of this technology in the delivery of nanoscale agents to folate receptor positive cancer cells. In this review I will examine the current status and role of folate targeted nanoconjugates for both diagnostic imaging and therapy.